

Erratum for “Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations”

Stephen K. Field

Division of Respiratory Medicine, University of Calgary, Calgary, Alberta, Canada.

This correction concerns Stephen K. Field, Roflumilast, a novel phosphodiesterase 4 inhibitor, for COPD patients with a history of exacerbations. *Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine*. 2011;5:57–70.

The full citation for the new version is: Stephen K. Field. Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations. *Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine*. 2011;5:57–70.

Corrections

1. Page 63, left column, 2nd sentence in the first paragraph: It is a selective not a nonselective PDE4i.
2. Page 63, left column, 1st paragraph of ‘Pharmacology of roflumilast’, 10th to 12 lines, should read: times to peak concentration are 0.9 and 4 hours and elimination half lives are 16 and 21 hours.
3. Page 64, right column, 3rd line from the top, 14% not 13% reduction.
4. Page 65, left column, last sentence of the first paragraph, the median time to the first AECOPD was greater not less in the roflumilast treated patients.
5. Page 66, right column, last sentence of the first paragraph in the summary, reference should be 76 not 75.
6. Page 67, table 6, last 2 rows of far right column, numbers are reversed, should be 1.9 vs. 2.4 and 1.8 vs. 2.2.

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 2012;6 51

doi: [10.4137/CCRPM.S10348](https://doi.org/10.4137/CCRPM.S10348)

This article is available from <http://www.la-press.com>.

© the author(s), publisher and licensee Libertas Academica Ltd.

This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.